Reneo Pharmaceuticals, Inc. (RPHM) |
7.39 -0.26 (-3.4%)
|
09-27 11:26 |
Open: |
7.61 |
Pre. Close: |
7.65 |
High:
|
7.93 |
Low:
|
7.32 |
Volume:
|
62,190 |
Market Cap:
|
250(M) |
|
|
Technical analysis |
as of: 2023-09-27 10:49:20 AM |
Short-term rate:
|
|
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Mid-term rate:
|
|
Target: |
Six months: 9.92 One year: 11.59 |
Support: |
Support1: 6.81 Support2: 5.78 |
Resistance: |
Resistance1: 8.5 Resistance2: 9.92 |
Pivot: |
7.28  |
Moving Average: |
MA(5): 7.56 MA(20): 7.06 
MA(100): 7.22 MA(250): 5.24  |
MACD: |
MACD(12,26): 0.2 Signal(9): 0.2  |
Stochastic oscillator: |
%K(14,3): 69.1 %D(3): 75.4  |
RSI: |
RSI(14): 60.3  |
52-week: |
High: 11.29 Low: 1.78 |
Average Vol(K): |
3-Month: 137 (K) 10-Days: 140 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RPHM ] has closed below upper band by 15.3%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
8.51 - 8.56 |
8.56 - 8.6 |
Low:
|
7.5 - 7.55 |
7.55 - 7.59 |
Close:
|
7.58 - 7.66 |
7.66 - 7.73 |
|
Company Description |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
Headline News |
Fri, 22 Sep 2023 Prelude Capital Management LLC Invests $89000 in Reneo ... - MarketBeat
Tue, 29 Aug 2023 Reneo Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire
Thu, 10 Aug 2023 Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy - Yahoo Finance
Mon, 31 Jul 2023 Should Biotechnology Stock Reneo Pharmaceuticals Inc (RPHM) Be in Your Portfolio Monday? - InvestorsObserver
Mon, 26 Jun 2023 Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices - Yahoo Finance
Mon, 05 Jun 2023 Is Reneo Pharmaceuticals Inc (RPHM) Stock a Good Value Monday? - InvestorsObserver
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
34 (M) |
Shares Float |
15 (M) |
% Held by Insiders
|
2 (%) |
% Held by Institutions
|
58.9 (%) |
Shares Short
|
2,030 (K) |
Shares Short P.Month
|
1,470 (K) |
Stock Financials |
EPS
|
-2.25 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
3.92 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
0 |
Return on Assets (ttm)
|
-29.2 |
Return on Equity (ttm)
|
-47.8 |
Qtrly Rev. Growth
|
0 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
-1.94 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-52 (M) |
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
PE Ratio
|
-3.42 |
PEG Ratio
|
0 |
Price to Book value
|
1.95 |
Price to Sales
|
0 |
Price to Cash Flow
|
-5.04 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|